Christopher J Cooper1, Timothy P Murphy, Donald E Cutlip, Kenneth Jamerson, William Henrich, Diane M Reid, David J Cohen, Alan H Matsumoto, Michael Steffes, Michael R Jaff, Martin R Prince, Eldrin F Lewis, Katherine R Tuttle, Joseph I Shapiro, John H Rundback, Joseph M Massaro, Ralph B D'Agostino, Lance D Dworkin. 1. From the University of Toledo, Toledo, OH (C.J.C.); Rhode Island Hospital (T.P.M., L.D.D.) and Alpert Medical School of Brown University (T.P.M., L.D.D.) - both in Providence; Harvard Clinical Research Institute (D.E.C., J.M.M., R.B.D.), Beth Israel Deaconess Medical Center (D.E.C.), Massachusetts General Hospital (M.R.J.), Brigham and Women's Hospital (E.F.L.), and Boston University School of Public Health (R.B.D.) - all in Boston; University of Michigan, Ann Arbor (K.J.); University of Texas Health Science Center, San Antonio (W.H.); National Heart, Lung and Blood Institute, Bethesda, MD (D.M.R.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (D.J.C.); University of Virginia, Charlottesville (A.H.M.); University of Minnesota, Minneapolis (M.S.); Weill Cornell Medical Center, New York (M.R.P.); Providence Sacred Heart Medical Center and University of Washington School of Medicine, Spokane (K.R.T.); Marshall University, Huntington, WV (J.I.S.); and Holy Name Medical Center, Teaneck NJ (J.H.R.).
Abstract
BACKGROUND:Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prevention of major adverse renal and cardiovascular events is uncertain. METHODS: We randomly assigned 947 participants who had atherosclerotic renal-artery stenosis and either systolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease tomedical therapy plus renal-artery stenting or medical therapy alone. Participants were followed for the occurrence of adverse cardiovascular and renal events (a composite end point of death from cardiovascular or renal causes, myocardial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficiency, or the need for renal-replacement therapy). RESULTS: Over a median follow-up period of 43 months (interquartile range, 31 to 55), the rate of the primary composite end point did not differ significantly between participants who underwent stenting in addition to receiving medical therapy and those who received medical therapy alone (35.1% and 35.8%, respectively; hazard ratio with stenting, 0.94; 95% confidence interval [CI], 0.76 to 1.17; P=0.58). There were also no significant differences between the treatment groups in the rates of the individual components of the primary end point or in all-cause mortality. During follow-up, there was a consistent modest difference in systolic blood pressure favoring the stent group (-2.3 mm Hg; 95% CI, -4.4 to -0.2; P=0.03). CONCLUSIONS: Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease. (Funded by the National Heart, Lung and Blood Institute and others; ClinicalTrials.gov number, NCT00081731.).
RCT Entities:
BACKGROUND:Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prevention of major adverse renal and cardiovascular events is uncertain. METHODS: We randomly assigned 947 participants who had atherosclerotic renal-artery stenosis and either systolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease to medical therapy plus renal-artery stenting or medical therapy alone. Participants were followed for the occurrence of adverse cardiovascular and renal events (a composite end point of death from cardiovascular or renal causes, myocardial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficiency, or the need for renal-replacement therapy). RESULTS: Over a median follow-up period of 43 months (interquartile range, 31 to 55), the rate of the primary composite end point did not differ significantly between participants who underwent stenting in addition to receiving medical therapy and those who received medical therapy alone (35.1% and 35.8%, respectively; hazard ratio with stenting, 0.94; 95% confidence interval [CI], 0.76 to 1.17; P=0.58). There were also no significant differences between the treatment groups in the rates of the individual components of the primary end point or in all-cause mortality. During follow-up, there was a consistent modest difference in systolic blood pressure favoring the stent group (-2.3 mm Hg; 95% CI, -4.4 to -0.2; P=0.03). CONCLUSIONS: Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease. (Funded by the National Heart, Lung and Blood Institute and others; ClinicalTrials.gov number, NCT00081731.).
Authors: U Blum; B Krumme; P Flügel; A Gabelmann; T Lehnert; C Buitrago-Tellez; P Schollmeyer; M Langer Journal: N Engl J Med Date: 1997-02-13 Impact factor: 91.245
Authors: M W Burket; C J Cooper; D J Kennedy; P S Brewster; G M Ansel; J A Moore; J Venkatesan; W L Henrich Journal: Am Heart J Date: 2000-01 Impact factor: 4.749
Authors: Christopher J Cooper; Timothy P Murphy; Alan Matsumoto; Michael Steffes; David J Cohen; Michael Jaff; Richard Kuntz; Kenneth Jamerson; Diane Reid; Kenneth Rosenfield; John Rundback; Ralph D'Agostino; William Henrich; Lance Dworkin Journal: Am Heart J Date: 2006-07 Impact factor: 4.749
Authors: M B Harding; L R Smith; S I Himmelstein; K Harrison; H R Phillips; S J Schwab; J B Hermiller; C J Davidson; T M Bashore Journal: J Am Soc Nephrol Date: 1992-05 Impact factor: 10.121
Authors: P N Harden; M J MacLeod; R S Rodger; G M Baxter; J M Connell; A F Dominiczak; B J Junor; J D Briggs; J G Moss Journal: Lancet Date: 1997-04-19 Impact factor: 79.321
Authors: Liesbeth Bax; Arend-Jan J Woittiez; Hans J Kouwenberg; Willem P T M Mali; Erik Buskens; Frederik J A Beek; Branko Braam; Frans T M Huysmans; Leo J Schultze Kool; Matthieu J C M Rutten; Cornelius J Doorenbos; Johannes C N M Aarts; Ton J Rabelink; Pierre-François Plouin; Alain Raynaud; Gert A van Montfrans; Jim A Reekers; Anton H van den Meiracker; Peter M T Pattynama; Peter J G van de Ven; Dammis Vroegindeweij; Abraham A Kroon; Michiel W de Haan; Cornelis T Postma; Jaap J Beutler Journal: Ann Intern Med Date: 2009-05-04 Impact factor: 25.391
Authors: Carmen C Beladan; Oliviana D Geavlete; Simona Botezatu; Marin Postu; Bogdan A Popescu; Carmen Ginghina; Ioan M Coman Journal: Tex Heart Inst J Date: 2017-02-01
Authors: A Eirin; S M Herrmann; A Saad; A Abumoawad; H Tang; A Lerman; S C Textor; L O Lerman Journal: Acta Physiol (Oxf) Date: 2019-03-13 Impact factor: 6.311
Authors: Aaron L Schwartz; Bruce E Landon; Adam G Elshaug; Michael E Chernew; J Michael McWilliams Journal: JAMA Intern Med Date: 2014-07 Impact factor: 21.873
Authors: Tanya N Turan; Jenifer H Voeks; Marc I Chimowitz; Ana Roldan; Todd LeMatty; William Haley; Maria Lopes-Virella; Seemant Chaturvedi; Michael Jones; Donald Heck; George Howard; Brajesh K Lal; James F Meschia; Thomas G Brott Journal: Stroke Date: 2020-09-21 Impact factor: 7.914
Authors: Abdelrhman Abumoawad; Ahmed Saad; Christopher M Ferguson; Alfonso Eirin; Sandra M Herrmann; LaTonya J Hickson; Busra B Goksu; Emily Bendel; Sanjay Misra; James Glockner; Allan B Dietz; Lilach O Lerman; Stephen C Textor Journal: Kidney Int Date: 2019-12-13 Impact factor: 10.612